Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| (NASDAQ: BMEA) | Delayed: 0.64 -0.05 (7.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.69 | 52 Week High | $ | |||
| Open | $0.66 | 52 Week Low | $ | |||
| Day High | $0.70 | P/E | N/A | |||
| Day Low | $0.63 | EPS | $ | |||
| Volume | 848,087 | |||||
